What Is a Biomarker?
In clinical medicine, a biomarker is a measurable indicator of a biological process, condition, or response to treatment. Inflammatory biomarkers are molecules whose concentrations change in response to immune activation. They serve as proxies — indirect measurements that correlate with, but are not identical to, the underlying disease process. Understanding what each marker actually reflects is essential for avoiding over-interpretation.
C-Reactive Protein (CRP)
CRP is an acute-phase protein synthesised by the liver in response to interleukin-6 (IL-6) stimulation. It rises within 6–8 hours of an inflammatory stimulus and has a half-life of approximately 19 hours. High-sensitivity CRP (hs-CRP) assays detect lower concentrations and are used in cardiovascular risk stratification. In gastroenterology, CRP is useful for monitoring IBD activity, but it has significant limitations: up to 30% of Crohn's disease patients and many ulcerative colitis patients do not mount a robust CRP response even during active flares. CRP is also non-specific — infections, surgery, malignancy, and autoimmune conditions all elevate it.
Fecal Calprotectin
Unlike CRP, which reflects systemic inflammation, fecal calprotectin is a gut-specific marker. It detects neutrophilic infiltration into the intestinal lumen with high sensitivity for mucosal inflammation. Its principal advantage is anatomical specificity: an elevated calprotectin strongly suggests gut-origin inflammation, whereas CRP could originate from any body system. However, calprotectin cannot localise disease within the GI tract, nor does it distinguish between causes of intestinal inflammation (IBD, infection, NSAID damage, colorectal neoplasia).
Erythrocyte Sedimentation Rate (ESR)
ESR measures how quickly red blood cells settle in a test tube over one hour. Elevated ESR reflects increased fibrinogen and immunoglobulins — both acute-phase reactants — and is a slow, non-specific indicator of inflammation. It changes more gradually than CRP and is influenced by age, sex, anaemia, and pregnancy. In gastroenterology, ESR adds modest value in monitoring chronic disease activity but is rarely used as a standalone diagnostic tool.
Emerging Markers
Research continues to evaluate novel biomarkers with greater specificity. Fecal lactoferrin (another neutrophil-derived protein), serum interleukins (IL-6, IL-8, IL-17), oncostatin M, and fecal S100A12 are under investigation for their ability to predict treatment response, distinguish disease phenotypes, and detect subclinical relapse. The AGA's 2023 guideline on biomarkers in ulcerative colitis management emphasises integrating multiple markers rather than relying on any single test.
The Big Picture
No biomarker is a diagnosis. Each reflects a specific slice of biology — hepatic acute-phase response (CRP), intestinal neutrophilic activity (calprotectin), or generalised protein-phase shifts (ESR). Clinicians combine biomarker trends with symptoms, endoscopy, and histology to build a composite picture. Patients benefit from understanding that a "normal" CRP does not exclude intestinal inflammation, and an elevated calprotectin does not confirm IBD — context always matters.